Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04287686
Other study ID # GIRH-APN01
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date February 2020
Est. completion date April 2020

Study information

Verified date March 2020
Source The First Affiliated Hospital of Guangzhou Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, randomized, controlled, pilot clinical study in patients with COVID-19, to obtain preliminary biologic, physiologic, and clinical data in patients with COVID-19 treated with rhACE2 or control patients, to help determine whether a subsequent Phase 2B trial is warranted.


Description:

This is a small pilot study investigating whether there is any efficacy signal that warrants a larger Phase 2B trial, or any harm that suggests that such a trial should not be done. It is not expected to produce statistically significant results in the major endpoints. The investigators will examine all of the biologic, physiological, and clinical data to determine whether a Phase 2B trial is warranted.

Primary efficacy analysis will be carried only on patients receiving at least 4 doses of active drug. Safety analysis will be carried out on all patients receiving at least one dose of active drug.

It is planned to enroll more than or equal to 24 subjects with COVID-19. It is expected to have at least 12 evaluable patients in each group.

Experimental group: 0.4 mg/kg rhACE2 IV BID and standard of care Control group: standard of care

Intervention duration: up to 7 days of therapy

No planned interim analysis.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Laboratory diagnosis:

- Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR,

- The viral gene sequencing of the respiratory specimen is highly homologous to known novel coronavirus.

2. Fever:

Axillary temperature >37.3?

3. Respiratory variables (meets one of the following criteria):

- Respiratory rate: RR =25 breaths/min

- Oxygen saturation =93% at rest on room air

- PaO2/FiO2 =300 mmHg(1 mmHg=0.133 KPa)

- Pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed as severe

4. HBsAg negative, or HBV DNA =10^4 copy/ml if HBsAg positive; anti-HCV negative; HIV negative two weeks prior to signed Informed Consent Form (ICF)

5. Appropriate ethics approval and

6. ICF

Exclusion Criteria:

- Age <18 years; Age >80 years

- Pregnant or breast feeding woman or with positive pregnancy test result

- P/F <100 mmHg

- Moribund condition (death likely in days) or not expected to survive for >7 days

- Refusal by attending MD

- Not hemodynamically stable in the preceding 4 hours (MAP =65 mmHg, or SAP <90 mmHg, DAP <60 mmHg, vasoactive agents are required)

- Patient on invasive mechanical ventilation or ECMO

- Patient in other therapeutic clinical trial within 30 days before ICF

- Receive any other ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB) treatment within 7 days before ICF

- Chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before ICF

- Hematologic malignancy (lymphoma, leukemia, multiple myeloma)

- Other patient characteristics (not thought to be related to underlying COVID-19) that portend a very poor prognosis (e.g, severe liver failure, and ect)

- Known allergy to study drug or its ingredients related to renin-angiotensin system (RAS), or frequent and/or severe allergic reactions with multiple medications

- Other uncontrolled diseases, as judged by investigators

- Body weight =85 kg

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Recombinant human angiotensin-converting enzyme 2 (rhACE2)
In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.

Locations

Country Name City State
China GCP Office of The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time course of body temperature (fever) Compare the time course of body temperature (fever) between two groups over time. 14 days
Primary Viral load over time Compare viral load between two groups over time. 14 days
Secondary P/F ratio over time PaO2/FiO2 ratio 14 days
Secondary Sequential organ failure assessment score(SOFA score) over time SOFA, including assessment of respiratory, blood, liver, circulatory, nerve, kidney, from 0 to 4 scores in each systems, the higher scores mean a worse outcome. 14 days
Secondary Pulmonary Severity Index (PSI) 14 days
Secondary Image examination of chest over time Based on radiologist's assessment of inflammatory exudative disease, category as follows: significant improvement, partial improvement, no improvement, increase of partial exudation, significant increase in exudation, unable to judge. 14 days
Secondary Proportion of subjects who progressed to critical illness or death 14 days
Secondary Time from first dose to conversion to normal or mild pneumonia 14 days
Secondary T-lymphocyte counts over time 14 days
Secondary C-reactive protein levels over time 14 days
Secondary Angiotensin II (Ang II) changes over time 14 days
Secondary Angiotensin 1-7 (Ang 1-7) changes over time 14 days
Secondary Angiotensin 1-5 (Ang 1-5) changes over time 14 days
Secondary Renin changes over time 14 days
Secondary Aldosterone changes over time 14 days
Secondary Angiotensin-converting enzyme (ACE) changes over time 14 days
Secondary Angiotensin-converting enzyme 2 (ACE2) changes over time 14 days
Secondary Interleukin 6 (IL-6) changes over time 14 days
Secondary Interleukin 8 (IL-8) changes over time 14 days
Secondary Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time 14 days
Secondary Plasminogen activator inhibitor type-1 (PAI-1) changes over time 14 days
Secondary Von willebrand factor (vWF) changes over time 14 days
Secondary Tumor necrosis factor-a (TNF-a) changes over time 14 days
Secondary Soluble receptor for advanced glycation end products (sRAGE) changes over time 14 days
Secondary Surfactant protein-D (SP-D) changes over time 14 days
Secondary Angiopoietin-2 changes over time 14 days
Secondary Frequency of adverse events and severe adverse events 14 days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure